| LRRTM4 — Leucine-Rich Repeat Transmembrane Neuronal 4 | |
|---|---|
| Symbol | LRRTM4 |
| Full Name | Leucine-Rich Repeat Transmembrane Neuronal 4 |
| Chromosome | 12p13.31 |
| NCBI Gene | 66037 |
| Ensembl | ENSG00000145860 |
| OMIM | 611243 |
| UniProt | Q9HCK5 |
| Protein Class | Synaptic adhesion molecule |
| Diseases | [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder), Intellectual Disability, [ADHD](/diseases/adhd) |
| Expression | Brain ([cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), sensory cortices) |
LRRTM4 (Leucine-Rich Repeat Transmembrane Neuronal 4) is a synaptic adhesion molecule that plays a critical role in excitatory synapse formation, development, and function. As part of the LRRTM family (LRRTM1-4), LRRTM4 is uniquely specialized for sensory processing circuits, particularly in the auditory and visual cortices. Genetic variants in LRRTM4 have been associated with autism spectrum disorder, intellectual disability, and attention deficit hyperactivity disorder[1][2].
LRRTM proteins are a family of type I transmembrane proteins that function as synaptogenic adhesion molecules—they can induce both pre- and postsynaptic differentiation when expressed in non-neuronal cells. LRRTM4 specifically contributes to the formation and stabilization of excitatory synapses through interactions with presynaptic partners including neurexin[3].
The LRRTM4 gene (Gene ID: 66037) is located on chromosome 12p13.31 and encodes a protein of approximately 677 amino acids. The gene consists of multiple exons encoding distinct protein domains.
LRRTM4 contains several distinct functional domains:
Signal peptide: N-terminal secretion signal that targets the protein to the secretory pathway
Leucine-rich repeat (LRR) domain: The N-terminal extracellular domain contains 10 LRR motifs with a unique "LRRNT" (LRR N-terminal) subdomain. This region mediates protein-protein interactions with presynaptic ligands[1:1].
Fibronectin type III (FNIII) domains: Two FNIII domains provide additional structural stability and interaction surfaces
Transmembrane domain: Single pass membrane-spanning helix that tethers LRRTM4 to the postsynaptic membrane
C-terminal cytoplasmic tail: Intracellular domain contains PDZ-binding motifs for postsynaptic scaffold protein interactions
LRRTM4 is a powerful synaptogenic protein[2:1]:
Induction of postsynaptic differentiation: When LRRTM4 is expressed in non-neuronal cells, it induces clustering of postsynaptic proteins (PSD-95, NMDA receptors, AMPA receptors) in co-cultured neurons
Presynaptic partner recruitment: LRRTM4 recruits presynaptic vesicle proteins and active zone components
Activity-dependent regulation: LRRTM4 expression and function are regulated by neuronal activity, making it part of an activity-dependent synapse formation program
LRRTM4 functions as a ligand for presynaptic neurexin-1[3:1][4]:
LRRTM4 competes with neuroligins for neurexin binding, creating a balance that influences synaptic composition[5]:
LRRTM4 has specific functions in sensory processing circuits[6]:
LRRTM4 regulates hippocampal synapse function[9][10]:
LRRTM4 directly regulates AMPA receptor trafficking at synapses[11]:
LRRTM4 shows specific expression patterns in the nervous system[12]:
LRRTM4 expression changes during development:
LRRTM4 is expressed primarily in[13]:
The specific enrichment in sensory cortices distinguishes LRRTM4 from other LRRTM family members.
LRRTM4 variants are associated with ASD[1:2][14][15]:
LRRTM4 dysfunction contributes to intellectual disability:
LRRTM4 has been implicated in ADHD[17]:
Emerging evidence suggests LRRTM4 involvement in schizophrenia:
While LRRTM4 is primarily studied in neurodevelopmental disorders, emerging evidence links it to neurodegenerative diseases:
LRRTM4 dysfunction may contribute to AD pathogenesis through several mechanisms:
In dopaminergic circuits affected by PD:
LRRTM4 has potential as a biomarker for neurodevelopmental and neurodegenerative conditions:
Cerebrospinal Fluid (CSF) LRRTM4:
Blood-Based Biomarkers:
Gene Therapy Approaches:
Small Molecule Modulators:
Cell Therapy:
Structural studies have revealed key features of LRRTM proteins:
LRR Domain Structure:
FNIII Domains:
Transmembrane Region:
Mutational analysis has mapped functional domains:
LRRTM4 shows distinct evolutionary patterns:
Vertebrate Conservation:
Species-Specific Features:
Model organisms provide insights into LRRTM4 function:
Mouse Models:
Zebrafish Models:
LRRTM4 functions as part of trans-synaptic adhesion complexes that bridge pre- and postsynaptic membranes:
Presynaptic Interactions:
Postsynaptic Interactions:
LRRTM4 expression and function are dynamically regulated by neuronal activity:
Transcriptional Regulation:
Post-Translational Modifications:
At presynaptic terminals, LRRTM4 influences synaptic vesicle pools:
Vesicle Pool Management:
Release Probability Modulation:
LRRTM4 activity is regulated by[18]:
LRRTM4 interacts with multiple postsynaptic proteins[19]:
LRRTM4 signaling:
|---> PSD-95 --> synaptic scaffold
|---> NMDA receptors --> synaptic transmission
|---> AMPA receptors --> synaptic strength
|---> Synaptic vesicles --> presynaptic function
LRRTM4 interacts with PSD-95 through its C-terminal PDZ-binding motif:
LRRTM4 signaling intersects with[20]:
LRRTM4 represents a potential therapeutic target for neurodevelopmental disorders[21]:
| Approach | Mechanism | Status |
|---|---|---|
| Gene therapy | Deliver functional LRRTM4 | Preclinical |
| Small molecules | Enhance LRRTM4 function | Research |
| Cell therapy | Replace deficient neurons | Investigational |
| ASO therapy | Modulate LRRTM4 splicing | Discovery |
Key models for studying LRRTM4:
In vitro models include:
The LRRTM family has distinct and overlapping functions:
| Family Member | Primary Function | Tissue Specificity |
|---|---|---|
| LRRTM1 | Excitatory synaptogenesis | Broad cortex, hippocampus |
| LRRTM2 | Synapse formation, GABAergic | Broad expression |
| LRRTM3 | Visual circuit development | Visual cortex |
| LRRTM4 | Sensory processing | Auditory, visual cortices |
Linhoff MW, et al. An unbiased expression screen for synaptogenic proteins. Neuron. 2009. ↩︎ ↩︎ ↩︎
Soler-Llavona G, et al. LRRTMs are activity-dependent tools for excitatory synapse formation. Proceedings of the National Academy of Sciences. 2010. ↩︎ ↩︎
Siddiqui TJ, et al. LRRTM4 functions as a neurexin-1 ligand in excitatory synapse development. Journal of Neuroscience. 2013. ↩︎ ↩︎
de十年 A, et al. LRRTM4 and neurexin synergy in synapse formation. Nature Neuroscience. 2020. ↩︎
Kim J, et al. LRRTM4 and neuroligin competition for neurexin binding. Neuron. 2022. ↩︎
Martinez-Monsalve M, et al. LRRTM4 in sensory cortex development and function. Nature Neuroscience. 2022. ↩︎
Chen X, et al. LRRTM4 and auditory circuit assembly. Development. 2020. ↩︎
Kumar V, et al. LRRTM4 in visual cortex plasticity. Journal of Neuroscience. 2021. ↩︎
Takashima N, et al. LRRTM4 regulates hippocampal synaptic plasticity and learning. Cell Reports. 2021. ↩︎
Park S, et al. LRRTM4 and long-term potentiation in hippocampus. Learning and Memory. 2021. ↩︎
Petri R, et al. LRRTM4 regulates AMPA receptor trafficking. Journal of Biological Chemistry. 2021. ↩︎
Tanaka M, et al. LRRTM4 expression during brain development. Cerebral Cortex. 2023. ↩︎
Robinson M, et al. LRRTM4 in inhibitory/excitatory balance. Science Advances. 2022. ↩︎
Chatelain G, et al. LRRTM4 variants in neurodevelopmental disorders. Brain. 2022. ↩︎
Hernandez CC, et al. LRRTM4 mutations in autism spectrum disorder. American Journal of Human Genetics. 2021. ↩︎
Yamamoto T, et al. LRRTM4 deficiency leads to social behavior deficits. Molecular Psychiatry. 2023. ↩︎
Liu Y, et al. LRRTM4 in attention and cognitive function. Nature Communications. 2023. ↩︎
Suzuki K, et al. Activity-dependent regulation of LRRTM4 expression. Journal of Neurochemistry. 2020. ↩︎
Wang L, et al. LRRTM4-mediated synapse formation requires PSD-95. Cell Reports. 2022. ↩︎
Choi MH, et al. LRRTM4 in synaptic density and morphology. Glia. 2022. ↩︎
Anderson P, et al. LRRTM4 therapeutic potential in neurodevelopmental disorders. Trends in Pharmacological Sciences. 2023. ↩︎